凝血酶/抗凝血酶复合体(TAT)等多因子检测试剂盒(流式荧光发光法)
Multiplex Assay Kit for Thrombin/Antithrombin Complex (TAT) ,etc. by FLIA (Flow Luminescence Immunoassay)
（注：单次混测多因子不超过8个指标 ）
产品包装(模拟)
产品包装(模拟)
通过ISO 9001、ISO 13485质量体系认证
特异性
本试剂盒用于检测凝血酶/抗凝血酶复合体(TAT)等多因子检测试剂盒(流式荧光发光法)，经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制，不可能完成对所有相关或相似物质交叉反应检测，因此本试剂盒有可能与未经检测的其它物质有交叉反应。
回收率
分别于定值血清及血浆样本中加入一定量的凝血酶/抗凝血酶复合体(TAT)等多因子检测试剂盒(流式荧光发光法)（加标样品），重复测定并计算其均值，回收率为测定值与理论值的比率。
| 样本 | 回收率范围(%) | 平均回收率(%) |
| serum(n=5) | 84-91 | 87 |
| EDTA plasma(n=5) | 79-98 | 86 |
| heparin plasma(n=5) | 95-104 | 101 |
精密度
精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差：取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次，分别计算不同浓度样本的平均值及SD值。
批间差：选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定，每个样本使用同一试剂盒重复测定8次，分别计算不同浓度样本的平均值及SD值。
批内差： CV<10%
批间差： CV<12%
线性
在定值血清及血浆样本内加入适量的凝血酶/抗凝血酶复合体(TAT)等多因子检测试剂盒(流式荧光发光法)，并倍比稀释成1:2，1:4，1:8，1:16的待测样本，线性范围即为稀释后样本中凝血酶/抗凝血酶复合体(TAT)等多因子检测试剂盒(流式荧光发光法)含量的测定值与理论值的比率。
| 样本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 91-98% | 86-96% | 88-102% | 83-101% |
| EDTA plasma(n=5) | 92-105% | 89-97% | 90-101% | 94-101% |
| heparin plasma(n=5) | 83-96% | 85-101% | 83-98% | 95-102% |
稳定性
经测定，试剂盒在有效期内按推荐温度保存，其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响，实验室的环境条件需尽量保持一致，尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
实验流程
1. 实验前标准品、试剂及样本准备；
2. 加样（标准品、样本、磁珠）标准品或样本100μL及磁珠10μL，
37°C酶标板振荡器孵育90分钟；
3. 磁吸甩干，加检测溶液A100μL，37°C酶标板振荡器孵育60分钟；
4. 磁吸洗板3次；
5. 加检测溶液B100μL，37°C振动孵育30分钟；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋涡震荡2分钟后读数。
实验原理
将凝血酶/抗凝血酶复合体(TAT)等多因子检测试剂盒(流式荧光发光法)抗体包被于磁珠，制成固相载体，向微孔中分别加入标准品或标本以及磁珠，其中的凝血酶/抗凝血酶复合体(TAT)等多因子检测试剂盒(流式荧光发光法)与连接于固相载体上的抗体结合，然后加入生物素化的凝血酶/抗凝血酶复合体(TAT)等多因子检测试剂盒(流式荧光发光法)抗体，将未结合的生物素化抗体洗净后，加入PE标记的亲和素，再次彻底洗涤后即可上机读数。MFI值和样品中的凝血酶/抗凝血酶复合体(TAT)等多因子检测试剂盒(流式荧光发光法)呈正相关。
赠品
增值服务
相关产品
| 编号 | 适用物种：Rattus norvegicus (Rat，大鼠) | 应用(仅供研究使用，不用于临床诊断！) |
| SEA831Ra | 凝血酶/抗凝血酶复合体(TAT)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA831Ra | 凝血酶/抗凝血酶复合体(TAT)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
| 杂志 | 参考文献 |
| IUBMB LIFE | Genetic repression of mouse VEGF expression regulates coagulation cascade.[PubMed: 21086498] |
| Thrombosis Research | Treatment with unfractionated heparin attenuates coagulation and inflammation in endotoxemic mice[ScienceDirect: S0049384811004166] |
| Journal of Thrombosis and Haemostasis | High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortality[Wiley: source] |
| 3 | Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodelling[Nature: 20120329] |
| Am J Respir Cell Mol Bio | Prolonged Exposure to Sphingosine 1–Phosphate Receptor-1 Agonists Exacerbates Vascular Leak, Fibrosis, and Mortality after Lung Injury[PubMed: PMC2993087] |
| PLoS One | Host Defense Peptides of Thrombin Modulate Inflammation and Coagulation in Endotoxin-Mediated Shock and Pseudomonas aeruginosa Sepsis[PubMed: PMC3521733] |
| Haemetology | Clinical impact of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations among sickle cell disease patients of Central India[Pubmed: 23992124] |
| Am J Transl Res. | Selected hemostatic parameters in patients with pancreatic tumors.[Pubmed:Pmc4297344] |
| PLOS ONE | TFPI1 Mediates Resistance to Doxorubicin in Breast Cancer Cells by Inducing a Hypoxic-Like Response[Pubmed:24489651] |
| Leukemia | Novel evidence that crosstalk between the complement, coagulation and fibrinolysis proteolytic cascades is involved in mobilization of hematopoietic stem/progenitor cells (HSPCs)[Pubmed:24667943] |
| Anesthesia & Analgesia | Thrombomodulin Improved Liver Injury, Coagulopathy, and Mortality in an Experimental Heatstroke Model in Mice[Pubmed:24781566] |
| Cell Transplantation | Evidence of a Pivotal Role for the Distal Part of the Complement Cascade in the Diurnal Release of Hematopoietic Stem Cells Into Peripheral Blood[Pubmed:26087465] |
| European Journal of Pharmacology | (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coaCavia (Guinea pig )lation[Pubmed:27343380] |
| J Thromb Haemost. | Coagulation factor XI vaccination: an alternative strategy to prevent thrombosis.[pubmed:27813324] |
| Blood Cells, Inflammation and Infection | Nebulized Heparin Attenuates Pulmonary Coagulopathy and Inflammation through Alveolar Macrophages in a Rat Model of Acute Lung Injury[pubmed:29202212] |
| SCIENCE TRANSLATIONAL MEDICINE | Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension[pubmed:28148841] |
| 32 | Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target[pubmed:28289017] |
| Thrombosis andHaemostasis | Nebulized anti-coagulants as a therapy for acute lung injury and acute respiratory distress syndrome[Pubmed: 29202212] |
| Thrombosis Research | The circadian rhythm of selected parameters of the hemostasis system in healthy people[] |
| Experimental Neurobiology | Transduced Tat-aldose Reductase Protects Hippocampal Neuronal Cells against Oxidative Stress-induced Damage[Pubmed: 31698553] |
| LIVER TRANSPLANTATION | The impact of dabigatran treatment on sinusoidal protection against hepatic ischemia‐reperfusion injury in mice[Pubmed: 33108682] |
| Am J Physiol Heart Circ Physiol | Doxorubicin contributes to thrombus formation and vascular injury via enhancing platelet functions in vivo[Pubmed: 32469636] |
| Intensive Care Medicine Experimental | Preservation of renal endothelial integrity and reduction of renal edema by aprotinin does not preserve renal perfusion and function following experimental …[34169407] |
| Intensive Care Med Exp | Complement factor D is linked to platelet activation in human and rodent sepsis[34396466] |